PYXS Insider Trading Activity and SEC Form 4 Filings
PYXS insider trading summary
Over the past 12 months, insiders at Pyxis Oncology, Inc. (PYXS) reported 4 open-market purchases worth $0 by 4 insiders and 1 sale worth $107K by 1 insider on SEC Form 4. Net insider selling was $107K.
Latest PYXS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 1, 2026 | GordonMD Long Biased GP LLC | 10% Owner | Buy | $0 (5,517,000 @ $0.00) |
| Oct 1, 2026 | GordonMD Long Biased Master Fund LP | 10% Owner | Buy | $0 (5,517,000 @ $0.00) |
| Oct 1, 2026 | Craig D Gordon | 10% Owner | Buy | $0 (5,517,000 @ $0.00) |
| Oct 1, 2026 | GordonMD Global Investments LP | 10% Owner | Buy | $0 (5,517,000 @ $0.00) |
| Jun 30, 2026 | Jakob Dupont | Insider | Sell | $107K (35,000 @ $3.06) |
| Apr 21, 2025 | Rachel Humphrey | Insider | Sell | $14K (13,896 @ $1.03) |
| Apr 17, 2025 | Rachel Humphrey | Insider | Sell | $194 (200 @ $0.97) |
| Apr 14, 2025 | Rachel Humphrey | Insider | Sell | $1K (1,400 @ $0.97) |
| Nov 26, 2024 | Pamela Ann Connealy | CFO & COO | Buy | $11K (5,450 @ $2.00) |
| Nov 26, 2024 | Pamela Ann Connealy | CFO & COO | Buy | $163K (83,400 @ $1.96) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.